Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...
On the first Sunday of November, when the majority of the United States set their clocks an hour earlier, the resulting ...
The FDA approved nerandomilast tablets for adults with progressive pulmonary fibrosis, according to an industry press release ...
HHS has announced proposed regulations that, if finalized, would limit access to gender-affirming care in minors and ...
Individuals with epilepsy and their caregivers want improved communication and a broader base of information from their ...
A 63-year-old Vietnamese-speaking man with a history of scleritis in the left eye, epiretinal membrane, dry eye syndrome and ...
GLP-1s improved outcomes in patients with heart failure with preserved ejection fraction, with or without obesity, but those ...
The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...
Toxic chemicals in some nail products can be hazardous to the skin and nails, causing allergic contact dermatitis, ...
In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, discusses results from the phase 2 EPCORE-DLBCL-3 trial, presented at the ASH Annual Meeting and Exposition. In stage 2 of the trial, researchers ...
Neuroimmune modulation could be an “emerging therapeutic approach” for patients with rheumatoid arthritis who had incomplete response or intolerance to anti-TNF therapy, according to Minna Kohler, MD, ...
In this video, Stephen M. Ansell, MD, PhD, discusses long-term outcomes from a large prospective cohort study of patients with follicular lymphoma, presented at ASH Annual Meeting and Exposition.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback